Loxo Oncology (NASDAQ:LOXO) Institutional Investors Q1 2018 Sentiment

June 19, 2018 - By Kenneth Lin

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

Sentiment for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ:LOXO) institutional sentiment increased to 1.16 in 2018 Q1. Its up 0.19, from 0.97 in 2017Q4. The ratio is positive, as 72 hedge funds increased and started new equity positions, while 62 cut down and sold holdings in Loxo Oncology. The hedge funds in our partner’s database now own: 30.09 million shares, down from 124.82 million shares in 2017Q4. Also, the number of hedge funds holding Loxo Oncology in their top 10 equity positions decreased from 5 to 4 for a decrease of 1. Sold All: 9 Reduced: 53 Increased: 40 New Position: 32.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $5.37 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

The stock decreased 0.40% or $0.72 during the last trading session, reaching $178.45. About 338,765 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 248.86% since June 19, 2017 and is uptrending. It has outperformed by 236.29% the S&P500.

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on August, 14. They expect $-0.57 earnings per share, up 50.00 % or $0.57 from last year’s $-1.14 per share. After $-0.12 actual earnings per share reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts 375.00 % negative EPS growth.

Aisling Capital Llc holds 70.71% of its portfolio in Loxo Oncology, Inc. for 3.44 million shares. Dafna Capital Management Llc owns 181,537 shares or 10.19% of their US portfolio. Moreover, Opaleye Management Inc. has 5.92% invested in the company for 179,400 shares. The New York-based Awm Investment Company Inc. has invested 1.89% in the stock. Driehaus Capital Management Llc, a Illinois-based fund reported 405,615 shares.

Since January 1, 0001, it had 0 buys, and 20 selling transactions for $24.63 million activity.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Ratings analysis reveals 90% of Loxo Oncology’s analysts are positive. Out of 10 Wall Street analysts rating Loxo Oncology, 9 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $102.0 while the high is $225. The stock’s average target of $180.75 is 1.29% above today’s ($178.45) share price. LOXO was included in 15 notes of analysts from December 20, 2017. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, March 1 report. Stifel Nicolaus maintained the shares of LOXO in report on Monday, June 4 with “Buy” rating. As per Thursday, May 17, the company rating was maintained by Stifel Nicolaus. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, May 9 report. The firm has “Buy” rating given on Wednesday, May 30 by Piper Jaffray. On Monday, March 5 the stock rating was maintained by Citigroup with “Buy”. IFS Securities downgraded the shares of LOXO in report on Tuesday, June 5 to “Market Perform” rating. The stock has “Market Outperform” rating by JMP Securities on Monday, June 4. The firm earned “Overweight” rating on Monday, June 4 by Morgan Stanley. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Overweight” rating given on Monday, April 16 by Morgan Stanley.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: Seekingalpha.com which released: “Financial Exchange Stock Talk: Joe McCann On Loxo Oncology” on May 29, 2018, also Nasdaq.com with their article: “Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers …” published on June 02, 2018, Nasdaq.com published: “New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star …” on June 07, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: Globenewswire.com and their article: “FDA Accepts Larotrectinib New Drug Application and Grants Priority Review” published on May 29, 2018 as well as Benzinga.com‘s news article titled: “Loxo Oncology’s Candidates Are ‘Impressive,’ Piper Jaffray Says In Bullish Initiation” with publication date: May 31, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: